{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:07:10Z","timestamp":1773299230098,"version":"3.50.1"},"reference-count":60,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Premenopausal women with bleeding disorders represent a major public health problem. Estimates suggest up to 20% of women with menorrhagia have an underlying bleeding disorder (corresponding to a prevalence of 1.5\u20134 million American women). Von Willebrand disease (VWD) is the most common bleeding disorder among women with menorrhagia, affecting up to 20% of such patients. Besides menorrhagia, important consequences of bleeding disorders in premenopausal women include iron deficiency anemia, miscarriage, postpartum bleeding, uterine bleeding and hysterectomy. These patients face many obstacles in achieving optimum care. Recognition is difficult as women may consider their symptoms \u201cnormal\u201d and come to attention only after serious bleeding events. Symptoms of VWD may also overlap with benign conditions, primary providers may not suspect the diagnosis, and convenient hematologic input may be unavailable. Diagnosis is difficult as there is no single definitive test for VWD, and test results are variable, often being affected by extragenic factors, including stress, contraceptives, hormones, and pregnancy. Hemostatic treatment is limited by DDAVP tachyphylaxis, the lack of recombinant VWD concentrates, and the ineffectiveness of hormonal therapy, leading to unnecessary procedures and early hysterectomy. Finally, significant controversy exists regarding classification of type 1 VWD as a disease: given the overlap in symptoms and laboratory assays within the normal population, evaluation for those with VWD might be seen as identification of potential bleeding risk rather than detection of a disease. This symposium seeks to explore these issues in greater detail from the combined perspectives of the obstetrician-gynecologist and the hematologist to promote a better public health approach to this problem.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.474","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T18:14:02Z","timestamp":1164219242000},"page":"474-485","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Bleeding Disorders in Premenopausal Women: (Another) Public Health Crisis for Hematology?"],"prefix":"10.1182","volume":"2006","author":[{"given":"Andra H.","family":"James","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent J.","family":"Picozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111703413350900_R1","doi-asserted-by":"crossref","unstructured":"Lalonde A. Evaluation of surgical options in menorrhagia. Br J Obstet Gynecol. 1994;101:8\u201314.","DOI":"10.1111\/j.1471-0528.1994.tb13689.x"},{"key":"2019111703413350900_R2","unstructured":"Shaw RW. Treating the patient with menorrhagia. Br J Obstet Gynaecol.1994;101(Suppl 11):1\u20132."},{"key":"2019111703413350900_R3","doi-asserted-by":"crossref","unstructured":"Fraser IS. Menorrhagia\u2014a pragmatic approach to the understanding of causes and the need for investigations. Br J Obstet Gynaecol.1994;101(Suppl 11):3\u20137.","DOI":"10.1111\/j.1471-0528.1994.tb13688.x"},{"key":"2019111703413350900_R4","doi-asserted-by":"crossref","unstructured":"Edlund M, Blomback M, von Schoultz B, Andersson D. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol. 1996;53:234\u2013238.","DOI":"10.1002\/(SICI)1096-8652(199612)53:4<234::AID-AJH4>3.0.CO;2-Z"},{"key":"2019111703413350900_R5","doi-asserted-by":"crossref","unstructured":"Ragni MV, Bontempo FA, Cortese-Hassett AL. Von Willebrand disease and bleeding in women. Haemophilia. 1999;5:313\u2013317.","DOI":"10.1046\/j.1365-2516.1999.00342.x"},{"key":"2019111703413350900_R6","unstructured":"The Diagnosis, Evaluation, and Management of Von Willebrand Disease. National Institutes of Health, National Heart, Lung, and Blood Institute. 2006, in press."},{"key":"2019111703413350900_R7","unstructured":"Working Group Report: Women with Bleeding Disorders. The National Heart Lung, and Blood Institute, June 2004, http:\/\/www.nhlbi.nih.gov\/meetings\/workshops\/wbd.htm"},{"key":"2019111703413350900_R8","unstructured":"Edlund M, Blomback, B., von Schoultz, et al. 1996. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol. 1996:53(4):234\u2013238."},{"key":"2019111703413350900_R9","doi-asserted-by":"crossref","unstructured":"Kadir RA, Economides DL, Sabin CA, et al. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998;351(9101):485\u2013489.","DOI":"10.1016\/S0140-6736(97)08248-2"},{"key":"2019111703413350900_R10","unstructured":"Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol. 2001;97(4):630\u2013636."},{"key":"2019111703413350900_R11","doi-asserted-by":"crossref","unstructured":"Goodman-Gruen D, Hollenbach K. The prevalence of von Willebrand disease in women with abnormal uterine bleeding. J Womens Health Gend Based Med. 2001;10(7):677\u2013680.","DOI":"10.1089\/15246090152563551"},{"key":"2019111703413350900_R12","unstructured":"Krause ME, Aygroren-Pursun S, Ehrenforth G, et al. Inherited and acquired coagulation disorders in women with menorrhagia. Thromb Haemost. 2001;86S (July Suppl):1137."},{"key":"2019111703413350900_R13","doi-asserted-by":"crossref","unstructured":"Woo YL, White B, Corbally R, et al. Von Willebrand\u2019s disease: an important cause of dysfunctional uterine bleeding. Blood Coagul Fibrinol. 2002;13(2):89\u201393.","DOI":"10.1097\/00001721-200203000-00003"},{"key":"2019111703413350900_R14","doi-asserted-by":"crossref","unstructured":"James AH, Lukes AS, Brancazio LR, et al. Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia. Am J Obstet Gynecol2004;191(2):449\u2013455.","DOI":"10.1016\/j.ajog.2004.03.009"},{"key":"2019111703413350900_R15","doi-asserted-by":"crossref","unstructured":"Phillipp CS, Dilley A, Miller CH, et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost. 2003;1(3):477\u2013484.","DOI":"10.1046\/j.1538-7836.2003.00061.x"},{"key":"2019111703413350900_R16","doi-asserted-by":"crossref","unstructured":"Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160\u2013174.","DOI":"10.1055\/s-0037-1613992"},{"key":"2019111703413350900_R17","doi-asserted-by":"crossref","unstructured":"Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893\u2013898.","DOI":"10.1016\/S0022-3476(05)80384-1"},{"key":"2019111703413350900_R18","doi-asserted-by":"crossref","unstructured":"Biron CB, Mahieu A, Rochette X, et al. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med. 1999;134(6):605\u2013609.","DOI":"10.1016\/S0022-2143(99)90100-2"},{"key":"2019111703413350900_R19","doi-asserted-by":"crossref","unstructured":"Ginsburg D, Bowie EJ. Molecular genetics of von Willebrand disease. Blood. 1992;79(10):2507\u20132519.","DOI":"10.1182\/blood.V79.10.2507.2507"},{"key":"2019111703413350900_R20","unstructured":"von Willebrand E. Hereditar pseudohemofili. Finiska Lakaresalskapets Handlingar.1926;LXVII(2):87\u2013112."},{"key":"2019111703413350900_R21","doi-asserted-by":"crossref","unstructured":"Kirtava A, Crudder S, Dilley A, et al. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States. Haemophilia. 2004;10(2):158\u2013161.","DOI":"10.1046\/j.1351-8216.2003.00832.x"},{"key":"2019111703413350900_R22","unstructured":"ACOG. Management of anovulatory bleeding. American College of Obstetricians and Gynecologists. 2000;1\u201312."},{"key":"2019111703413350900_R23","unstructured":"Silwer J. von Willebrand\u2019s disease in Sweden. Acta Paediatr Scand Suppl. 1973;238:1\u2013159."},{"key":"2019111703413350900_R24","doi-asserted-by":"crossref","unstructured":"Weiss RM. Case presentation: a patient with von Willebrand disease with menorrhagia. Am J Obstet Gynecol. 1996:175(3 Pt 2):763\u2013765.","DOI":"10.1016\/S0002-9378(96)80081-0"},{"key":"2019111703413350900_R25","doi-asserted-by":"crossref","unstructured":"Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost. 2005:3(4):775\u2013777.","DOI":"10.1111\/j.1538-7836.2005.01245.x"},{"key":"2019111703413350900_R26","doi-asserted-by":"crossref","unstructured":"Kirtava A, Drews C, Lally C, et al. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand\u2019s disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia. 2003;9(3):292\u2013297.","DOI":"10.1046\/j.1365-2516.2003.00756.x"},{"key":"2019111703413350900_R27","doi-asserted-by":"crossref","unstructured":"James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia. 2005;11(4):295\u2013307.","DOI":"10.1111\/j.1365-2516.2005.01108.x"},{"key":"2019111703413350900_R28","doi-asserted-by":"crossref","unstructured":"Von Willebrand EA. Hereditary pseudohaemophilia. Haemophilia.1999;5(3):223\u2013231; discussion 222.","DOI":"10.1046\/j.1365-2516.1999.00302.x"},{"key":"2019111703413350900_R29","doi-asserted-by":"crossref","unstructured":"Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood. 2003;101(6):2089\u20132093.","DOI":"10.1182\/blood-2002-09-2892"},{"key":"2019111703413350900_R30","doi-asserted-by":"crossref","unstructured":"James A, Matchar DB, Myers ER. Testing for von Willebrand disease in women with menorrhagia: a systematic review. Obstet Gynecol. 2004:104(2):381\u2013388.","DOI":"10.1097\/01.AOG.0000133487.55682.7b"},{"key":"2019111703413350900_R31","doi-asserted-by":"crossref","unstructured":"Larsson G, Milsom I, Lindstedt G, et al. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception. 1992;46(4):327\u2013334.","DOI":"10.1016\/0010-7824(92)90095-B"},{"key":"2019111703413350900_R32","doi-asserted-by":"crossref","unstructured":"Kaunitz AM. Menstruation: choosing whether and when. Contraception. 2000;62(6):277\u2013284.","DOI":"10.1016\/S0010-7824(00)00182-7"},{"key":"2019111703413350900_R33","doi-asserted-by":"crossref","unstructured":"Kingman CE, Kadir RA, Lee CA, et al. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. Bjog. 2004;111(12):1425\u20131428.","DOI":"10.1111\/j.1471-0528.2004.00305.x"},{"key":"2019111703413350900_R34","doi-asserted-by":"crossref","unstructured":"Von Willebrand disease in gynecologic practice. ACOG Committee Opinion No. 263. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2001;98:1186\u20131186.","DOI":"10.1016\/S0029-7844(01)01706-9"},{"key":"2019111703413350900_R35","doi-asserted-by":"crossref","unstructured":"Todd RF III. A guide to planning careers in hematology and oncology. Hematology (Am Soc Hematol Educ Program). 2001:499\u2013506.","DOI":"10.1182\/asheducation-2001.1.499"},{"key":"2019111703413350900_R36","doi-asserted-by":"crossref","unstructured":"Yang YM, Ragni MV. Clinical manifestations and management of labor and delivery in women with factor IX deficiency. Haemophilia. 2004;10:483\u2013490.","DOI":"10.1111\/j.1365-2516.2004.00946.x"},{"key":"2019111703413350900_R37","unstructured":"Orstavik KH, Magnus P, Reisner H, et al. W. Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet. 1985;37:89\u2013101."},{"key":"2019111703413350900_R38","doi-asserted-by":"crossref","unstructured":"Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69:1691\u20131695.","DOI":"10.1182\/blood.V69.6.1691.1691"},{"key":"2019111703413350900_R39","doi-asserted-by":"crossref","unstructured":"Lethagen S, Isaksson C, Schaedel C, et al. Von Willebrand disease caused by compound heterozygosity for a substitution mutation (T1156M) in the D3 domain of the von Willebrand factor and a stop mutation (Q2470X). Thromb Haemost. 2003;88:421\u2013426.","DOI":"10.1055\/s-0037-1613232"},{"key":"2019111703413350900_R40","doi-asserted-by":"crossref","unstructured":"Brown SA, Eldridge A, Collins PW, et al. Increased clearance of von Willebrand factor antigen post-DDAVP in type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost. 2003;1:1714\u20131717.","DOI":"10.1046\/j.1538-7836.2003.00359.x"},{"key":"2019111703413350900_R41","unstructured":"Drews CD, Dilley AB, Lally C, et al. Screening questions to identify women with von Willebrand disease. J Am Med Womens Assoc. 2002;57:217\u2013218."},{"key":"2019111703413350900_R42","doi-asserted-by":"crossref","unstructured":"Laffan M, Brown SA, Collins PW, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors\u2019 Organization. Haemophilia. 2004;10:199\u2013217.","DOI":"10.1111\/j.1365-2516.2004.00894.x"},{"key":"2019111703413350900_R43","doi-asserted-by":"crossref","unstructured":"Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. Am J Obstet Gynecol. 2004;190:1216\u20131223.","DOI":"10.1016\/j.ajog.2003.11.015"},{"key":"2019111703413350900_R44","doi-asserted-by":"crossref","unstructured":"Quiroga T, Goycoolea M, Munoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost. 2004;2:892\u2013898.","DOI":"10.1111\/j.1538-7836.2004.00693.x"},{"key":"2019111703413350900_R45","unstructured":"Schlesinger KW, Rinder HM, Ragni MV. Women with Bleeding Disorders. In Ehrenthal DB, Hoffman MK, Hillard PJ, eds. Women\u2019s Health Book Series: Menstrual Disorders. American College of Physicians\/American Society of Internal Medicine: Philadelphia; 2006:171\u2013195."},{"key":"2019111703413350900_R46","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2005;3:2619\u20132626.","DOI":"10.1111\/j.1538-7836.2005.01663.x"},{"key":"2019111703413350900_R47","doi-asserted-by":"crossref","unstructured":"Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4:766\u2013773.","DOI":"10.1111\/j.1538-7836.2006.01847.x"},{"key":"2019111703413350900_R48","doi-asserted-by":"crossref","unstructured":"Kouides PA, Phatak PD, Burkart P, et al. Gynecological and obstetrical morbidity in women with type 1 von Willebrand disease: results of a patient survey. Haemophilia. 2000;6:643\u2013648.","DOI":"10.1046\/j.1365-2516.2000.00447.x"},{"key":"2019111703413350900_R49","doi-asserted-by":"crossref","unstructured":"Gill JC, Ewenstein BM, Thompson AR, et al. Successful treatment of urgent bleeding in von Willebrand disease with VIII\/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003;9:688\u2013695.","DOI":"10.1046\/j.1351-8216.2003.00816.x"},{"key":"2019111703413350900_R50","doi-asserted-by":"crossref","unstructured":"Thompson AR, Gill JC, Ewenstein BM, et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII\/VWF concentrate (Humate-P). Haemophilia. 2004;10:42\u201351.","DOI":"10.1046\/j.1351-8216.2003.00809.x"},{"key":"2019111703413350900_R51","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Treatment of von Willebrand disease. N Engl J Med. 2004;351:683\u2013694.","DOI":"10.1056\/NEJMra040403"},{"key":"2019111703413350900_R52","doi-asserted-by":"crossref","unstructured":"Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003;1:682\u2013689.","DOI":"10.1046\/j.1538-7836.2003.00190.x"},{"key":"2019111703413350900_R53","doi-asserted-by":"crossref","unstructured":"Kadir RA, Lee CA, Sabin CA, et al. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia. 2002;8:787\u2013793.","DOI":"10.1046\/j.1365-2516.2002.00678.x"},{"key":"2019111703413350900_R54","doi-asserted-by":"crossref","unstructured":"Leissinger C, Becton D, Cornell C, et al. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild hemophilia A, mild, or moderate type 1 von Willebrand disease and symptomatic carriers of hemophilia A. Haemophilia. 2001;7:258\u2013256.","DOI":"10.1046\/j.1365-2516.2001.00500.x"},{"key":"2019111703413350900_R55","doi-asserted-by":"crossref","unstructured":"Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349:1443\u20131450.","DOI":"10.1056\/NEJMcp030751"},{"key":"2019111703413350900_R56","doi-asserted-by":"crossref","unstructured":"Milman N, Clausen J, Bug KE. Iron status in 268 Danish women aged 18\u201330 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol. 1998;77:13\u201319.","DOI":"10.1007\/s002770050405"},{"key":"2019111703413350900_R57","doi-asserted-by":"crossref","unstructured":"Rubin G, Wortman M, Kouides PA. Endometrial ablation for von Willebrand disease-related menorrhagia\u2013experience with seven cases. Haemophilia. 2004;10:477\u2013482.","DOI":"10.1111\/j.1365-2516.2004.00915.x"},{"key":"2019111703413350900_R58","doi-asserted-by":"crossref","unstructured":"Denis CV, Wagner DD, et al. Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood. 2001;97:465\u2013472.","DOI":"10.1182\/blood.V97.2.465"},{"key":"2019111703413350900_R59","doi-asserted-by":"crossref","unstructured":"Olsen EHN, McCain AS, Merricks EP, et al. Interleukin-11 upregulates vWF mRNA in dogs. Blood. 2003;102:436\u2013441.","DOI":"10.1182\/blood-2003-01-0290"},{"key":"2019111703413350900_R60","doi-asserted-by":"crossref","unstructured":"Friberg B, Orno AK, Lindgren A, et al. Bleeding disorders among young women: a population-based prevalence study. Acta Obstet Gynecol Scand. 2006;85(2):200\u2013206.","DOI":"10.1080\/00016340500342912"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/474\/1091711\/474_485ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/474\/1091711\/474_485ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T03:42:26Z","timestamp":1573962146000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/474\/19827\/Bleeding-Disorders-in-Premenopausal-Women-Another"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.474","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}